MX2022001061A - Agentes de interleuquina-2 y usos de los mismos. - Google Patents
Agentes de interleuquina-2 y usos de los mismos.Info
- Publication number
- MX2022001061A MX2022001061A MX2022001061A MX2022001061A MX2022001061A MX 2022001061 A MX2022001061 A MX 2022001061A MX 2022001061 A MX2022001061 A MX 2022001061A MX 2022001061 A MX2022001061 A MX 2022001061A MX 2022001061 A MX2022001061 A MX 2022001061A
- Authority
- MX
- Mexico
- Prior art keywords
- agents
- interleukine
- variants
- treat
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962879137P | 2019-07-26 | 2019-07-26 | |
| US202062983061P | 2020-02-28 | 2020-02-28 | |
| PCT/US2020/043416 WO2021021606A1 (en) | 2019-07-26 | 2020-07-24 | Interleukin-2 agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001061A true MX2022001061A (es) | 2022-02-14 |
Family
ID=72179191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001061A MX2022001061A (es) | 2019-07-26 | 2020-07-24 | Agentes de interleuquina-2 y usos de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12084484B2 (https=) |
| EP (1) | EP4004025A1 (https=) |
| JP (2) | JP7483857B2 (https=) |
| KR (1) | KR102943539B1 (https=) |
| CN (1) | CN114450298B (https=) |
| AU (1) | AU2020323893A1 (https=) |
| BR (1) | BR112022001415A2 (https=) |
| CA (1) | CA3147757A1 (https=) |
| IL (1) | IL290118A (https=) |
| MX (1) | MX2022001061A (https=) |
| MY (1) | MY209471A (https=) |
| PH (1) | PH12022550165A1 (https=) |
| TW (1) | TWI889694B (https=) |
| WO (1) | WO2021021606A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3147757A1 (en) * | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| JP2023525200A (ja) * | 2020-03-05 | 2023-06-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 設計されたｉｌ－２変異型 |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| KR20230147072A (ko) | 2021-01-20 | 2023-10-20 | 비스테라, 인크. | 인터류킨-2 돌연변이체 및 이의 용도 |
| CN112961245B (zh) * | 2021-02-24 | 2023-07-25 | 重庆精准生物技术有限公司 | 一种靶向cd96的双特异性抗体及其制备方法和用途 |
| CN112724263B (zh) * | 2021-04-02 | 2021-08-03 | 上海偌妥生物科技有限公司 | 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用 |
| WO2023281485A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| WO2023102463A1 (en) | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
| EP4475875A1 (en) * | 2022-02-11 | 2024-12-18 | Visterra, Inc. | Interleukin-2 muteins for the treatment of autoimmune diseases |
| CN114848808B (zh) * | 2022-03-24 | 2023-04-25 | 四川大学 | 基于阳离子脂多肽及细胞因子的免疫增强剂及制法、应用 |
| US20250215452A1 (en) | 2022-03-25 | 2025-07-03 | Universität Zürich | Adenoviral Mediated Targeting of Activated Immune Cells |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2024146575A1 (zh) * | 2023-01-04 | 2024-07-11 | 北京晶泰科技有限公司 | 白细胞介素-2变体及其应用 |
| WO2025040797A1 (en) * | 2023-08-23 | 2025-02-27 | Depth Charge Ltd | Interleukin-2 variant proteins that facilitate covalent chemical conjugation and uses thereof |
| CN119345372A (zh) * | 2024-10-28 | 2025-01-24 | 北京大学人民医院 | Cd132在治疗aml中的应用 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4908433A (en) | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0262802A3 (en) | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| ATE241011T1 (de) | 1991-02-27 | 2003-06-15 | Micromet Ag | Serin-reiche peptidlinker |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| BRPI0508470A (pt) | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| US20110200534A1 (en) | 2008-08-21 | 2011-08-18 | Industry-Academic Cooperation Foundation, Yonsei U | T1-T2 Dual Modal MRI Contrast Agents |
| KR100873651B1 (ko) | 2008-08-21 | 2008-12-11 | 김광한 | 잔디 식재기 |
| WO2010021526A2 (en) | 2008-08-22 | 2010-02-25 | Lg Electronics Inc. | A method for processing additional information related to an announced service or content in an nrt service and a broadcast receiver |
| WO2010021527A2 (ko) | 2008-08-22 | 2010-02-25 | Jung Tae Woo | 영상에 포함된 객체를 색인하는 시스템 및 방법 |
| KR101111286B1 (ko) | 2008-08-22 | 2012-03-14 | 한국생산기술연구원 | 발포체, 이 발포체의 제조장치, 이 발포체를 이용한 발포금속의 제조방법 및 발포금속 제조장치 |
| WO2010021520A2 (ko) | 2008-08-22 | 2010-02-25 | 엘지전자 주식회사 | 동기 채널 전송 방법 |
| KR100996532B1 (ko) | 2008-08-22 | 2010-11-24 | 주식회사 엠아이텍 | 탄소나노튜브 기반 바이오센서에서 링커와 스페이서를 이용한 민감도 증가 방법 |
| CN103772268B (zh) | 2008-08-22 | 2017-01-04 | 株式会社Lg化学 | 用于有机电子器件的材料以及使用所述材料的有机电子器件 |
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| KR102220006B1 (ko) | 2011-03-11 | 2021-02-24 | 아시스땅스 퍼블리끄-오삐또 드 빠리 | 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도 |
| ES2811624T3 (es) | 2011-03-11 | 2021-03-12 | Hopitaux Paris Assist Publique | Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| RS61391B1 (sr) | 2012-06-08 | 2021-02-26 | Alkermes Pharma Ireland Ltd | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| KR102042246B1 (ko) | 2014-02-06 | 2019-11-28 | 에프. 호프만-라 로슈 아게 | 인터류킨-2 융합 단백질 및 이의 용도 |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PH12017501856B1 (en) * | 2015-04-10 | 2022-08-10 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| MY188430A (en) | 2015-04-10 | 2021-12-08 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| RU2611685C2 (ru) | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR102687530B1 (ko) * | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| SG11201900616UA (en) | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
| US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| EP3580230B1 (en) | 2017-02-07 | 2026-04-22 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| WO2019112852A1 (en) | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US20210277085A1 (en) | 2017-05-24 | 2021-09-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US20210017247A1 (en) | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| MX2020003783A (es) | 2017-10-02 | 2021-01-08 | Visterra Inc | Moleculas de anticuerpo de cd138 y sus usos. |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3720470A4 (en) | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | IL-2 MUTEINS AND THEIR USES |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| MX2021000801A (es) | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| CA3147757A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| KR20230147072A (ko) | 2021-01-20 | 2023-10-20 | 비스테라, 인크. | 인터류킨-2 돌연변이체 및 이의 용도 |
| WO2023102463A1 (en) | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
| EP4475875A1 (en) | 2022-02-11 | 2024-12-18 | Visterra, Inc. | Interleukin-2 muteins for the treatment of autoimmune diseases |
-
2020
- 2020-07-24 CA CA3147757A patent/CA3147757A1/en active Pending
- 2020-07-24 JP JP2022505282A patent/JP7483857B2/ja active Active
- 2020-07-24 KR KR1020227005614A patent/KR102943539B1/ko active Active
- 2020-07-24 AU AU2020323893A patent/AU2020323893A1/en active Pending
- 2020-07-24 CN CN202080067804.7A patent/CN114450298B/zh active Active
- 2020-07-24 PH PH1/2022/550165A patent/PH12022550165A1/en unknown
- 2020-07-24 WO PCT/US2020/043416 patent/WO2021021606A1/en not_active Ceased
- 2020-07-24 MY MYPI2022000355A patent/MY209471A/en unknown
- 2020-07-24 MX MX2022001061A patent/MX2022001061A/es unknown
- 2020-07-24 TW TW109125207A patent/TWI889694B/zh active
- 2020-07-24 BR BR112022001415A patent/BR112022001415A2/pt unknown
- 2020-07-24 EP EP20760640.1A patent/EP4004025A1/en active Pending
- 2020-07-24 US US16/937,993 patent/US12084484B2/en active Active
-
2022
- 2022-01-25 IL IL290118A patent/IL290118A/en unknown
-
2024
- 2024-03-25 US US18/616,055 patent/US12297249B2/en active Active
- 2024-05-01 JP JP2024074388A patent/JP7850199B2/ja active Active
- 2024-10-31 US US18/933,201 patent/US20250059249A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022541657A (ja) | 2022-09-26 |
| AU2020323893A1 (en) | 2022-02-17 |
| WO2021021606A1 (en) | 2021-02-04 |
| TW202118774A (zh) | 2021-05-16 |
| BR112022001415A2 (pt) | 2022-06-07 |
| CA3147757A1 (en) | 2021-02-04 |
| TWI889694B (zh) | 2025-07-11 |
| JP7483857B2 (ja) | 2024-05-15 |
| US20210024601A1 (en) | 2021-01-28 |
| CN114450298B (zh) | 2026-02-06 |
| JP7850199B2 (ja) | 2026-04-22 |
| PH12022550165A1 (en) | 2023-05-08 |
| KR20220051177A (ko) | 2022-04-26 |
| US20250059249A1 (en) | 2025-02-20 |
| US20240247040A1 (en) | 2024-07-25 |
| EP4004025A1 (en) | 2022-06-01 |
| KR102943539B1 (ko) | 2026-03-24 |
| IL290118A (en) | 2022-03-01 |
| MY209471A (en) | 2025-07-10 |
| CN114450298A (zh) | 2022-05-06 |
| JP2024102211A (ja) | 2024-07-30 |
| US12084484B2 (en) | 2024-09-10 |
| US12297249B2 (en) | 2025-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| DOP2019000266A (es) | Inhibidores de pd-1/pd-l1 | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
| MX388460B (es) | Composiciones de yodo. | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX2018013240A (es) | Composiciones antiirritantes sinergisticas de taurina y aloe. | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CL2019002574A1 (es) | Moduladores de la expresión de pcsk9. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| MX2017014245A (es) | Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas. | |
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2018014135A (es) | Tratamiento del dolor. | |
| CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
| MX2017014128A (es) | 2-tiopirimidinonas. |